Global pharmaceutical manufacturer Merck, also known as MSD outside the United States and Canada, will begin construction of its new $3 billion, 400,000-square-foot facility at the Elkton, Virginia, site.
In an Oct. 20 announcement, the company noted that the new Center for Excellence in Pharmaceutical Manufacturing is part of its $70 billion investment plan for manufacturing and research within the United States.
“Today is an important milestone for Merck, for Virginia, for manufacturing in the United States and, most importantly, for the patients we serve,” Robert M. Davis, Merck chairman and CEO, said in the statement.
“This investment helps advance our goal of providing new, innovative treatment options for people facing serious health challenges in the U.S. and around the world.”…